Answers are grounded in this paper and cite their sources.
This review traces the journey of regulatory B cells (Bregs), highlighting their dual role as immunomodulators and therapeutic targets.
For half a century, the quiet work of a specialized immunosuppressive B cell subset has been slowly unveiled, revealing its profound impact on immune balance. This review provides a comprehensive retrospective on the history of regulatory B cell (Breg) investigation, tracing their journey from initial elusive observations to their current recognition as crucial immunomodulators. We explore the paradigm shift from B cells solely as antibody producers to their multifaceted roles in immunosuppression. Key milestones include the earliest suggestions of suppressive B cell activity around 1970, the formal coining of the currently used term "regulatory B cells" in the early 2000s, and the subsequent elucidation of diverse Breg subsets and their suppressive mechanisms. Finally, we discuss contemporary advances, including the application of single-cell multi-omics, the identification of novel markers and metabolic regulators, and the promising yet challenging path toward Breg-based therapeutic strategies. This historical perspective underscores the remarkable progress in Breg biology and illuminates future directions for harnessing their clinical potential.
No takes yet. Share an insight, caveat, or question.
Zheremyan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: